Entrada Therapeutics Inc (TRDA) 13F Filing Data & Analysis (Q2 2026)

TRDA ranks #4007 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TRDA is a top-conviction position for 5AM Venture Management, LLC — at 10.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TRDA belongs to Baker Bros. Advisors LP, but the position matters far more to 5AM Venture Management, LLC, who has 10.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

IFP Advisors, Inc has added to its TRDA position for two straight quarters, increasing it by $2.1K to reach $2.1K today.

Versant Capital Management, Inc has trimmed its TRDA position for two straight quarters, cutting it by $24.4K while still holding $26.7K.

TRDA is down 6.4% today, but institutions show net buying of $33.2M this quarter — a divergence between today's price move and the underlying institutional flow.

TRDA reported a net loss of $165.8M over the trailing twelve months.

• Not yet profitable — net loss of $165.8M over the trailing twelve months
• Revenue declined 94.1% year over year
• Net income declined year over year, from -$73.4M to -$165.8M
• Operating cash flow was negative, using $128.5M in cash
• Current ratio of 12.53x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.23x equity — within a conventional range